Christian U. Blank

Bio

We haven't found any bio for you yet.

Researcher Links

0000-0002-7945-5846

Publications by Type

Loading publications…

The last 5 uploaded publications

View all

Figure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, Lucie Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, Mark R. Middleton, Carola Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, Anna Polli, Allison S. Harney, Alessandra di Pietro, Paolo A. Ascierto (2025). Figure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma. , DOI: https://doi.org/10.1158/1078-0432.29221276.
Preprint
62 days ago
Table 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, Lucie Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, Mark R. Middleton, Carola Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, Anna Polli, Allison S. Harney, Alessandra di Pietro, Paolo A. Ascierto (2025). Table 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma. , DOI: https://doi.org/10.1158/1078-0432.29221270.
Preprint
62 days ago
Table 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, Lucie Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, Mark R. Middleton, Carola Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, Anna Polli, Allison S. Harney, Alessandra di Pietro, Paolo A. Ascierto (2025). Table 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma. , DOI: https://doi.org/10.1158/1078-0432.29221267.
Preprint
62 days ago
Figure 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma
Allison S. Harney, Alessandra di Pietro, Paolo A. Ascierto, Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, Lucie Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, Mark R. Middleton, Carola Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, Anna Polli (2025). Figure 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma. , DOI: https://doi.org/10.1158/1078-0432.29221279.
Preprint
62 days ago
Supplementary Data 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma
Reinhard Dummer, Shahneen Sandhu, Wilson H. Miller, Marcus O. Butler, Matthew H. Taylor, Lucie Heinzerling, Christian U. Blank, Eva Muñoz‐Couselo, Howard A. Burris, Michael A. Postow, Bartosz Chmielowski, Mark R. Middleton, Carola Berking, Jessica C. Hassel, Anja Gesierich, Cornelia Mauch, Joseph F. Kleha, Anna Polli, Allison S. Harney, Alessandra di Pietro, Paolo A. Ascierto (2025). Supplementary Data 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with BRAFV600-Mutant Metastatic Melanoma. , DOI: https://doi.org/10.1158/1078-0432.29221273.
Preprint
62 days ago

Bio

Researcher Links

Publications by Type

The last 5 uploaded publications

Figure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma

Table 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma

Table 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma

Figure 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma

Supplementary Data 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma

Bio

Researcher Links

Publications by Type

The last 5 uploaded publications

Figure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600&lt;/sup&gt;-Mutant Metastatic Melanoma

Table 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600&lt;/sup&gt;-Mutant Metastatic Melanoma

Table 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600&lt;/sup&gt;-Mutant Metastatic Melanoma

Figure 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600&lt;/sup&gt;-Mutant Metastatic Melanoma

Supplementary Data 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with &lt;i&gt;BRAF&lt;/i&gt;&lt;sup&gt;V600&lt;/sup&gt;-Mutant Metastatic Melanoma

Figure 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma

Table 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma

Table 2 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma

Figure 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma

Supplementary Data 1 from Longitudinal Genomic Analysis to Fine-tune Targeted Therapy: Results of the Phase II LOGIC 2 Trial in Patients with <i>BRAF</i><sup>V600</sup>-Mutant Metastatic Melanoma